DEVELOPMENT AND LICENSE AGREEMENTAgreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations
Protocol AN01.01.0012 Change Order no. 2, 8th June 2006Amarin Corp Plc\uk • May 19th, 2008 • Pharmaceutical preparations
IN WITNESS WHEREOF, the parties hereto have executed this Change Order by their duly authorised representatives on the date(s) written below.
FORM OF SECURITIES PURCHASE AGREEMENTDeposit Agreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of May 13, 2008, is made by and among Amarin Corporation plc, a company incorporated under the laws of England and Wales (the “Company”), and the purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a “Purchaser” and collectively, the “Purchasers”).
PURCHASE AGREEMENTPurchase Agreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations • England and Wales
THIS CERTIFIES THAT, for value received, ______________, with its principal office at ______________, or assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from Amarin Corporation plc, a public limited company organized under the laws of England and Wales, with its principal office at 7 Curzon Street, London, W1J 5HG, United Kingdom (the “Company”), up to ______________ ordinary shares, par value £0.05 per share, of the Company (the “Ordinary Shares”), each Ordinary Share represented by one American Depositary Share (an “ADS”), evidenced by one American Depositary Receipt (an “ADR”), of the Company, subject to adjustment as provided herein. This warrant (the “Warrant”) is being issued pursuant to the terms of the Purchase Agreement, dated as of June 1, 2007, by and between the Holder and the Company (the “Purchase Agreement”). Capitalized terms not otherwise defined herein shall have the respective meanings ascribed to such terms in
Dated 18 January 2007 and and and AGREEMENT for termination and release of certain confidentiality obligations Reed Smith Rambaud Charot LLP Minerva House London SE1 9BB United Kingdom Tel: +44 20 7403 2900 Fax: +44 20 7403 4221 Ref: JNW/GPAgreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations • New York
NOW, THEREFORE, in consideration of the mutual promises and covenants contained in this Agreement and for other good and valuable consideration, the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations
THIS AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENT, dated as of April 7, 2008 (this “Agreement”), by and among Amarin Corporation plc, a public limited liability company incorporated under the laws of England and Wales (the “Buyer”) and Medica II Management L.P., a Cayman Islands limited partnership (the “Sellers’ Representative”), in its capacity as the Sellers’ Representative appointed pursuant to Section 13 of that certain Stock Purchase Agreement dated 5 December 2007 between Buyer, the Security Holders of Ester Neuroscience Ltd (the “Company”), the Company, and the Sellers’ Representative (the “SPA”; all capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them in the SPA).
DATED 9 DAY OF MARCH 2007 (1) AMARIN CORPORATION PLC and (2) DALRIADA LIMITED CORPORATE CONSULTANCY AGREEMENTConsultancy Agreement • May 19th, 2008 • Amarin Corp Plc\uk • Pharmaceutical preparations
ContractAmarin Corp Plc\uk • May 19th, 2008 • Pharmaceutical preparations • England
Certain portions of this Exhibit have been omitted pursuant to a request for “Confidential Treatment” under Rule 24b-2 of the Securities and Exchange Commission. Such portions have been redacted and bracketed in the request and appear as [*] in the text of this Exhibit. The omitted confidential information has been filed with the Securities and Exchange Commission.
